Pharmaceuticals, Biotechnology and Life Sciences
Corvus Pharmaceuticals’s study of its investigational small molecule T-cell signaling pathway inhibitorresults, indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity.
BerGenBio started testing has started testing anti-AXL therapeutic monoclonal antibody BGB149 with healthy volunteers in its fully own Phase I clinical trial.
Basilea Pharmaceutica’s analysis of the registrational phase 2 study of potential of derazantinib in the treatment of FGFR-driven tumors, also confirmed the safety profile and tolerability of the drug candidate observed in previous clinical studies.
Cellular Biomedicine Group (CBMG) will begin picking the patients to test anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.
Vast Therapeutics has a drug candidate, BIOC51, which is active against Bacillus anthracis, commonly known as anthrax, it said found out in an in vitro study carried out at Lovelace Biomedical.
Protagonist Therapeutics has injected mimetic peptide (PTG-300) into patients with beta thalassemia, to test it in a study to make it a treatment for this rare disease.
Amgen and UCB on Tuesday reported getting licence to market Evenity to treat patients with osteoporosis, who have high risk…
Omya has developed Omyasprint, an orally disintegrating tablet (ODT) based on the excipient Omyapharm and vitamin B 12.
Oncology focused pharmaceutical company Corvus Pharmaceuticals has started enrolling patients in the second arm of its ongoing Phase 1/1b dose-escalation study to test combination of CPI-006, a humanized monoclonal antibody directed against CD73, with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor.
Regen BioPharma’s researches have combined its lead NR2F6 small molecule agonist with Cannabidiol (CBD) to provide a dynamic therapy for treating inflammatory bowel disease (IBD), and it could work.